 BLACKSBURG, Va., April 26, 2021 GLOBE NEWSWIRE -- Landos Biopharma NASDAQ: LABP, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that two late-breaking abstracts on preclinical data of omilancor in psoriasis and proof-of concept preclinical data of PX-69 in rheumatoid arthritis will be presented at the upcoming American Association of Immunologists AAI Annual Meeting 2021. The meeting will be held virtually from May 10-15, 2021. 